MIV Therapeutics is a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices. It is developing coatings based on hydroxyapatite (HAp), hydroxyl Apatite (HAp) is a ceramic material with a similar composition to natural bone. These proprietary coatings show potential beyond current technologies and products, which release drugs after stent implantation. The microporous membrane is designed to maintain a high degree of biocompatibility even after all drug materials are eluted from the coating. In this regard, HAp performance far exceeds polymer-based coatings, where drugs are necessary to maintain acceptable coating performance.
Ultra-thin films are designated as surface-modifying materials for metal implants, and micro-thin films have also been evaluated as potential carriers for drug delivery purposes for implantable medical devices. In extremely demanding applications on nails, the coating must not only undergo deformation during manufacturing and implantation stages, but also remain intact during such operations. If this is not enough, the coating must maintain its integrity and resist fatigue stress, consistent with the heartbeat after deployment in the human heart.
Composite layer for genetic diagnosis
An effective and safe gene transfer system is a key technology in gene therapy and tissue engineering. DNA/calcium phosphate complex particles have long been used to promote gene transfer because of their low toxicity. However, compared with other reagents such as DNA/lipid complexes, the gene transfer efficiency of this reagent is insufficient. Recent studies have also shown that gene transfer and optimization at the DNA/apatite complex level are as effective as commercial lipid-based reagents.